Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS

NCT05795140 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

65

Enrollment

INDUSTRY

Sponsor class

Conditions

Atypical Hemolytic Uremic Syndrome

Interventions

DRUG: Iptcaopan 200 mg

Sponsor

Novartis Pharmaceuticals